(Q35154278)

6 August 2017

1 reference

title

An update expert opinion on management and research strategies in Parkinson's disease psychosis (English)

1 reference

6 August 2017

1 reference

1 reference

3

Christopher G Goetz

1 reference

6 August 2017

Jennifer G Goldman

1

1 reference

6 August 2017

Christina L Vaughan

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

2 June 2011

1 reference

Expert Opinion on Pharmacotherapy

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

13

1 reference

6 August 2017

page(s)

2009-2024

1 reference

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Neuropsychiatric symptoms in Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Epidemiology of psychosis in Parkinson's disease.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

5-HT(2A) inverse-agonists for the treatment of insomnia

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Scales to assess psychosis in Parkinson's disease: Critique and recommendations

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

The amphetamine-induced sensitized state as a model of schizophrenia

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Metabolic alterations in patients with Parkinson disease and visual hallucinations

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Polymorphisms in candidate genes: implications for the current treatment of Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Psychotic symptoms in Parkinson's disease. From description to etiology

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Rivastigmine for dementia associated with Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Medication-induced hallucination and cerebral blood flow in Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Hallucinosis in idiopathic Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Visual hallucinations associated with Parkinson disease.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Polymorphism in serotonin transporter gene associated with susceptibility to major depression.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Mortality and hallucinations in nursing home patients with advanced Parkinson's disease.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Risperidone for hallucinations in levodopa-treated Parkinson's disease patients

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Confusion, dementia and anticholinergics in Parkinson's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Simple schizophrenia: past, present, and future

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Levodopa-induced psychosis: a kindling phenomenon

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?

13 July 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Longitudinal outcome of Parkinson's disease patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Psychopathological features in patients with Parkinson's disease and related caregivers' burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Tactile hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Frégoli syndrome associated with levodopa treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

The pedunculopontine nucleus in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Serotonin 2A receptors and visual hallucinations in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Quetiapine for agitation or psychosis in patients with dementia and parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Olanzapine treatment for dopaminergic-induced hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Use of ziprasidone in parkinsonian patients with psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Cerebral atrophy in Parkinson's disease patients with visual hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Altered cortical visual processing in PD with hallucinations: an fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Visual hallucination in Parkinson's disease with FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.587122

Delusions associated with elevated muscarinic binding in dementia with Lewy bodies

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3152685

Pharmacology of hallucinations induced by long-term drug therapy

27 September 2018

1 reference

12 December 2020

Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial

1 reference

12 December 2020

Aripiprazole associated with severe exacerbation of Parkinson's disease

1 reference

12 December 2020

Clozapine and risperidone treatment of psychosis in Parkinson's disease

1 reference

12 December 2020

Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs

1 reference

12 December 2020

Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis

1 reference

12 December 2020

Nucleus ruber and L-Dopa psychosis: Biochemical post-mortem findings

1 reference

12 December 2020

Olfactory and visual hallucinations in Parkinson's disease

1 reference

12 December 2020

All-cause mortality associated with atypical and typical antipsychotics in demented outpatients

1 reference

12 December 2020

1 reference

12 December 2020

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

1 reference

12 December 2020

Dopamine action and disorders of neurotransmitter balance

1 reference

12 December 2020

Complications of chronic levodopa therapy: long-term efficacy of drug holiday

1 reference

12 December 2020

1 reference

12 December 2020

Melperone in the treatment of iatrogenic psychosis in Parkinson's disease

1 reference

12 December 2020

Antidepressants and psychosis in Parkinson disease: a case series

1 reference

12 December 2020

Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group

1 reference

12 December 2020

Scales to evaluate psychosis in Parkinson's disease

1 reference

12 December 2020

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease

1 reference

12 December 2020

10.1517/14656566.2011.587122

Identifiers

DOI

1 reference

6 August 2017

1 reference

6 August 2017

1 reference